Asthma and COPD Devices Market
Asthma and COPD Devices Market Size, Share & Industry Analysis, By Product Type (Inhalers, Nebulizers), By Indication (Asthma, COPD), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) - Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The Asthma and COPD Devices Market is projected to grow at a CAGR of 5.8% from 2024 to 2031. The market value is expected to increase from USD XX billion in 2024 to USD YY billion by 2031.
North America currently dominates the market, with key metrics indicating a high prevalence of asthma and COPD in the region. The market is experiencing steady growth due to increasing awareness about respiratory diseases, technological advancements in inhaler devices, and a growing aging population prone to respiratory ailments.
Market Dynamics:
Market Trend: Rising adoption of smart inhalers and connected devices for better disease management
The asthma and COPD device market is shifting significantly towards smart inhalers and connected devices. These new technologies use sensors and mobile applications to monitor medicine use, send reminders, and collect data on patient adherence and lung function. This trend is being pushed by the growing emphasis on personalised therapy and the need for improved disease management. Smart inhalers provide real-time monitoring and data analysis, allowing healthcare providers to make more educated judgements and change treatment programs accordingly. The incorporation of artificial intelligence and machine learning algorithms into these devices expands their capabilities, allowing for predictive analysis and early detection of exacerbations. As patients become more tech-savvy and seek greater control over their health, the use of smart inhalers is projected to increase, revolutionising how respiratory disorders are managed.
Market Driver: Increasing prevalence of asthma and COPD worldwide
Asthma and COPD are becoming more common around the world, which is a major driver of the market. According to the World Health Organisation, asthma affects more than 339 million people worldwide, whereas COPD affects around 384 million people. According to the Centres for Disease Control and Prevention, approximately 25 million individuals in the United States suffer with asthma, with 5.1 million children among them. Air pollution, smoking, occupational dangers, and genetic susceptibility all contribute to the increasing prevalence of these respiratory disorders. As the number of patients grows, so does the demand for effective and easy-to-use inhalers, nebulisers, and other respiratory equipment. Furthermore, the economic burden of chronic diseases, which is expected to be more than $80 billion per year in the United States, is causing healthcare systems to invest in improved management tools and technology, accelerating market growth.
Market Restraint: High cost of advanced inhaler devices limiting adoption in developing regions
The high cost of modern inhaler devices and smart inhalers poses a substantial barrier to market expansion, particularly in developing nations. While these devices improve medicine delivery and patient monitoring, their high cost often prevents them from reaching a large proportion of the patient population in poor and middle-income nations. According to studies, the expense of asthma and COPD therapy, including devices, can account for up to 25% of a family's income in some poor countries. This price burden causes poor treatment adherence and dependence on less effective, older generation devices, impeding total market growth in these locations.
Segment Overview:
Inhalers dominate the product type segment, driven by their convenience and effectiveness in drug delivery.
The inhalers sector dominates the asthma and COPD devices industry, accounting for over 70% of total sales. This dominance is due to the vast range of inhaler types available, such as metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs), which cater to various patient preferences and demands. Patients and healthcare providers choose inhalers because of their portability, convenience of use, and direct drug administration to the lungs.
Recent advances in inhaler technology have strengthened their commercial position. For example, the introduction of breath-actuated inhalers has addressed the prevalent issue of poor inhaler technique, resulting in increased medicine effectiveness. Industry giants such as GlaxoSmithKline and AstraZeneca have been at the forefront of innovation, introducing digital inhalers equipped with sensors that track usage trends and provide real-time feedback to patients and physicians.
The market has also seen an increase of ecologically friendly inhalers. Chiesi Farmaceutici introduced the first carbon minimum pressurised metered-dose inhaler (pMDI) for asthma and COPD in the United Kingdom in 2020, in response to growing environmental concerns. This approach has been well-received, with other corporations following suit, showing a shift towards more sustainable respiratory care options.
Regional Outlook:
North America leads the global asthma and COPD devices market, driven by high disease prevalence and advanced healthcare infrastructure.
North America dominates the asthma and COPD device industry, accounting for over 40% of the global total. The region's high frequency of respiratory disorders, well-established healthcare infrastructure, and early adoption of sophisticated medical technologies have all contributed to its leadership position. The United States, in particular, has been at the forefront of market growth, thanks to strong research and development efforts and favourable reimbursement regulations for respiratory devices.
Recent North American market trends indicate an increasing emphasis on digital health solutions for asthma and COPD management. For example, the FDA's approval of many digital medicines and connected inhaler devices has paved the door for more personalised and data-driven treatment strategies.
Key data highlight North America's vast commercial potential. According to the Centres for Disease Control and Prevention, approximately 25 million Americans suffer from asthma, and 16 million adults have COPD. These large patient numbers result in a significant demand for breathing devices.
In Canada, the government's emphasis on minimising the economic cost of respiratory disorders has resulted in increasing financing for innovative device development. The Canadian Respiratory Research Network's new initiative to improve COPD care through technology-enabled solutions is projected to accelerate market growth in the country.
Competitive Intelligence:
The asthma and COPD devices market is characterised by fierce rivalry among significant competitors, with an emphasis on innovation and strategic collaboration. Leading businesses like as GlaxoSmithKline, AstraZeneca, and Boehringer Ingelheim have considerable market shares because to their robust product portfolios and global presence. These firms are investing extensively in research and development to create next-generation inhalers and smart gadgets. For example, GlaxoSmithKline's Ellipta inhaler platform has grown significantly in popularity, contributing to the company's 18% market share in the respiratory area.
growing businesses, such as Teva Pharmaceutical and Lupin, are attacking established firms with aggressive price strategies and a focus on growing markets. Teva's recent development of digital inhalers in collaboration with Digihaler technology has established the company as a leading developer in the field.
M&A activity is altering the competitive landscape, as Vectura's acquisition by Philip Morris International in 2021 demonstrates non-traditional firms' increased interest in the respiratory devices sector. This tendency is likely to continue, potentially resulting in market consolidation and new competitive dynamics.
Financial analysis shows that the top five competitors jointly account for over 60% of market revenue. Regional businesses, on the other hand, are making inroads into developing markets by leveraging local manufacturing skills and distribution networks.
Companies are focussing on establishing integrated disease management systems, which combine devices with digital health solutions, to obtain a competitive advantage. The market is primed for greater change as internet companies enter the healthcare space, potentially disrupting existing business models in the coming years.
Analyst Opinion:
The market for asthma and COPD devices is expected to grow and shift significantly in the next years. The use of artificial intelligence and machine learning into respiratory devices is a crucial trend to watch, as it has the potential to transform disease management and patient outcomes. This technological development is anticipated to lead to more personalised treatment approaches and higher adherence rates.
Another notable aspect is the increased emphasis on environmentally friendly inhaler solutions. As worldwide awareness of climate change grows, we expect a trend towards propellant-free devices and recycling schemes for spent inhalers. This trend addresses not just environmental concerns, but also creates new opportunities for innovation and market distinction.
The COVID-19 pandemic has increased the use of telemedicine and remote patient monitoring in respiratory treatment. This move is projected to have long-term implications for the market, increasing demand for connected devices and digital health solutions that integrate seamlessly with telehealth platforms.
Finally, emerging markets in Asia Pacific and Latin America provide significant development potential. As healthcare infrastructure improves and awareness of respiratory disorders grows in these locations, we anticipate tailored product offers and strategic collaborations to capture these high-potential markets.
Major Players:
-
GlaxoSmithKline plc
-
AstraZeneca plc
-
Boehringer Ingelheim International GmbH
-
Novartis AG
-
Teva Pharmaceutical Industries Ltd.
-
OMRON Healthcare, Inc.
-
Koninklijke Philips N.V.
-
Sunovion Pharmaceuticals Inc.
-
Cipla Limited
-
Merck & Co., Inc.
Key Developments:
-
In June 2023, AstraZeneca got FDA approval for Breztri Aerosphere, a triple-combination therapy for COPD, increasing their respiratory portfolio.
-
In March 2023, Teva Pharmaceutical debuted their ProAir Digihaler (albuterol sulphate) Inhalation Powder in the United States, representing a significant leap in digital inhaler technology.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. GlaxoSmithKline plc
5.2. AstraZeneca plc
5.3. Boehringer Ingelheim International GmbH
5.4. Novartis AG
5.5. Teva Pharmaceutical Industries Ltd.
5.6. OMRON Healthcare, Inc.
5.7. Koninklijke Philips N.V.
5.8. Sunovion Pharmaceuticals Inc.
5.9. Cipla Limited
5.10. Merck & Co., Inc. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Rising adoption of smart inhalers and connected devices for better disease management
6.1.2. Increasing focus on environmentally sustainable inhaler solutions
6.1.3. Integration of AI and machine learning in respiratory devices
6.2. Market Drivers
6.2.1. Increasing prevalence of asthma and COPD worldwide
6.2.2. Technological advancements in inhaler devices
6.2.3. Growing aging population prone to respiratory ailments
6.3. Market Restraints
6.3.1. High cost of advanced inhaler devices limiting adoption in developing regions
6.3.2. Stringent regulatory requirements for device approval
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Inhalers
7.1.1. Metered Dose Inhalers (MDIs)
7.1.2. Dry Powder Inhalers (DPIs)
7.1.3. Soft Mist Inhalers (SMIs)
7.2. Nebulizers
7.2.1. Jet Nebulizers
7.2.2. Ultrasonic Nebulizers
7.2.3. Mesh Nebulizers
8. BY INDICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Asthma
8.2. COPD
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
Asthma and COPD Devices Market Segmentation:
By Product Type:
-
Inhalers
-
Metered Dose Inhalers (MDIs)
-
Dry Powder Inhalers (DPIs)
-
Soft Mist Inhalers (SMIs)
-
-
Nebulizers
-
Jet Nebulizers
-
Ultrasonic Nebulizers
-
Mesh Nebulizers
-
By Indication:
-
Asthma
-
COPD
By Distribution Channel:
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511